Antibiotic prophylaxis in surgery (ADULTS) Type of Surgery Antibiotic of Choice Alternative in true Penicillin Allergy or MRSA carriage

Size: px
Start display at page:

Download "Antibiotic prophylaxis in surgery (ADULTS) Type of Surgery Antibiotic of Choice Alternative in true Penicillin Allergy or MRSA carriage"

Transcription

1 These guidelines have been amended to reduce the incidence of Clostridium difficile associated diarrhoea and includes recommendations from the most recent guidance 1-8 NB. If patient is a VRE carrier or has had a recent VRE infection, please contact a Microbiologist for advice as standard antibiotics will be ineffective. Important notes: Refer to British National Formulary for further details of cautions, contra-indications, side effects and dosages 1. The pre-operative antimicrobial dose should be administered within 30 minutes before skin incision. However, give prophylaxis earlier for operations in which a tourniquet is used 2. An additional dose of antibiotic prophylaxis may be given during operations 1,2 a. lasting more than 4 hours b. in the event of major intra-operative blood loss (>1500ml). additional dosage of prophylactic antibiotics should be consider after fluid replacement 3. Antibiotic prophylaxis should be confined to the perioperative period only Postoperative doses should not be given, unless stated in the guidance or agreed with Microbiology 4. When severe renal impairment known or suspected please contact Pharmacy or Microbiology department for advice 5. If history of life threatening allergy to penicillin (e.g. anaphylaxis, angioedema, facial/throat swelling), consult microbiology/pharmacy for advice 6. Avoid cephalosporins (cefuroxime) in all patients 7. Alternative antibiotics should only be given if the patient has a penicillin allergy or is colonised or infected with MRSA 8. Where prophylaxis is not given when recommended, should be clearly recorded in the case records 9. With gentamicin, the risk of ototoxicity may be increased by other ototoxic drugs, e.g. furosemide. The risk of nephrotoxicity is increased by other drugs e.g. NSAIDs, cephalosporins, vancomycin and amphotericin. 7 Gentamicin key points 10. Gentamicin doses over 240 mg should be given as a 30 to 60 min infusion 11. Gentamicin Intravenous bolus injection should be given over 3 minutes Gentamicin- Maximum dose of 500mg OD 13. Gentamicin may interact with neuromuscular blocking agents e.g. suxamethonium used during anaesthesia, and can enhance the potential neuromuscular blockade 7 Orthopaedic surgery Total hip replacement Prosthetic knee joint Replacement (regardless of use of antibiotic cement) Hip fracture repair Spinal surgery Insertion of prosthetic Device Revision arthroplasty Major trauma/open fractures Co-amoxiclav 1.2 g IV at, followed by a second dose 8 hours later, and a final dose 8 hours later (total of 3 doses in 24 hours) Single dose Co-amoxiclav 1.2 g IV at Can be used for the following: Platings, metalwork insertion, metalwork removal, joint injections Antibiotics should NOT be given until samples have been taken Single dose Teicoplanin 10mg/kg IV (to nearest 100mg, maximum 800mg) stat after sampling + Meropenem 500mg IV stat bolus after sampling If sepsis syndrome followed by: Teicoplanin 10mg/kg IV (to nearest 100mg, maximum 800mg) 12 hourly for 3 doses then OD + Meropenem 500mg TDS IV Stop meropenem after 48 hours if no Gramnegatives on cultures and continue with teicoplanin until final cultures available, then seek advice from Microbiology Co-amoxiclav 1.2 g IV at, followed by a second dose 8 hours later, and a final dose 8 hours later (total of 3 doses in 24 hours) If Grossly contaminated add in: Metronidazole 500mg IV 8 hourly (2 doses) + Gentamicin 1.5mg/kg IV stat bolus at Consider extending treatment until definitive surgical procedure performed 800mg) stat at + Gentamicin 1.5mg/kg IV stat bolus at 800mg) 12 hours after first dose (two doses in total) Antibiotics should NOT be given until samples have been taken Single dose 800mg) stat after sampling + Gentamicin 1.5mg/kg IV stat bolus at If sepsis syndrome followed by: 800mg) 12 hourly for 3 doses then OD + Gentamicin 5mg/kg* IV as 30 to 60min infusion OD from day 2 onwards Gentamicin and Teicoplanin levels ARE required 800mg) stat at + Gentamicin 1.5mg/kg IV stat bolus at + Metronidazole 500mg IV stat at 800mg) 12 hours after first dose (two doses in total) + Metronidazole 500mg IV 8 hourly (2 doses) Consider extending treatment until definitive surgical procedure performed (additional gentamicin from day 2 onwards required. Gentamicin levels ARE required) Orthopaedic surgery without prosthetic device (elective) * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW (ABW-IBW). ; 1 of 6

2 Obstetrics and Gynaecology Caesarean section Hysterectomy (abdominal or vaginal) Perineal tear third or fourth degree involving anal sphincter/rectal mucosa Manual removal of placenta Co-amoxiclav 1.2g i.v. stat at 9 During a caesarean section, prophylaxis could be delayed until the cord is clamped (at + Metronidazole 500mg i.v. stat Surgical termination of pregnancy Co-amoxiclav 1.2g i.v. stat at Plus Azithromycin 1gram PO if patient not screened for STDs prior to the procedure If PID suspected, please refer to the Trust Antibiotic Guidance or contact Microbiology or Sexual Health Medicine for further advice Assisted delivery Evacuation of complete mis Urology Transrectal prostate biopsy +/- Metronidazole 500mg i.v. stat at (at Hydrocoeles/hernia repair Transurethral resection of the prostate Transurethral resection of bladder tumours At surgeon s discretion may consider Nephrectomy +/- Metronidazole 500mg i.v. stat at (at At surgeon s discretion may consider Cystoscopy To be considered if high risk of UTI Ciprofloxacin 500 mg p.o. 1 hour before procedure (single dose) 8 If urine colonised with resistant organism: or contact Microbiology for targeted therapy To be considered if high risk of UTI Ciprofloxacin 500 mg p.o. 1 hour before procedure (single dose) 8 If urine colonised with resistant organism: or contact Microbiology for targeted therapy * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Dosing is based on actual body weight (ABW) unless patient is obese (20% over ideal body weight-(ibw)) Obese dosing weight= IBW+ 0.4 (ABW-IBW). 2 of 6

3 UPPER GASTROINTESTINAL Oesophageal surgery Stomach and duodenal surgery Gastric bypass surgery Small intestine surgery Endoscopic gastrostomy LOWER GASTROINTESTINAL Colorectal surgery 4-5 Appendicectomy Suspected or confirmed Ruptured viscus/ peritoneal contamination HEPATOBILIARY Gentamicin 5mg/kg* i.v. infusion over 30 min at +/- Amoxicillin 1g i.v. stat at (at If Treatment regimen required (post surgery) Piperacillin/Tazobactam 4.5g i.v. 8 hourly for 5 to 7 days +/- Amoxicillin 1g i.v. stat at (at Piperacillin/Tazobactam 4.5g i.v. at Piperacillin/Tazobactam 4.5g i.v. 8 hourly for 5 to 7 days 60min at +/- Teicoplanin 400mg i.v. stat (at surgeon s If Treatment regimen required (post surgery) Metronidazole 500mg i.v. 8 hourly + Teicoplanin 10mg/kg IV (to nearest 100mg: maximum 800mg) for 3 loading doses 12 hours apart then OD From day 2 add in: 60minutes OD Gentamicin and Teicoplanin levels ARE required +/- Teicoplanin 400mg i.v. stat (at surgeon s 60min at +/- Teicoplanin 400mg i.v. stat (at surgeon s If Treatment regimen required (post surgery) Metronidazole 500mg i.v. 8 hourly + Teicoplanin 10mg/kg IV (to nearest 100mg: maximum 800mg) for 3 loading doses 12 hours apart then OD From day 2 add in: 60minutes OD Gentamicin and Teicoplanin levels ARE required Biliary surgery (open) Pancreatic surgery Liver surgery Gall bladder surgery (open) +/- Amoxicillin 1g i.v. stat at (at Gall bladder surgery (laparoscopic) +/- Teicoplanin 400mg i.v. stat at (at Gentamicin and Teicoplanin levels NOT required * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW+ 0.4 (ABW-IBW). 3 of 6

4 ABDOMEN Pseudomyxoma peritonei Laparoscopic or nonlaparoscopic hernia repair with mesh Co-amoxiclav 1.2 g i.v. at, followed by a second dose 4 hours later And a final dose 8 hours later (total of 3 doses in 24 hours) followed by: Metronidazole 500mg i.v. 8 hourly (total of 3 doses in 24hours) Gentamicin 3mg/kg i.v. infusion over 30 to 60min at, +/- Teicoplanin 400 mg i.v. stat at Metronidazole 500mg i.v. 8 hourly (2 doses) + Teicoplanin 400 mg i.v. one additional dose at 12 hours Gentamicin and Teicoplanin levels NOT required Laparoscopic or nonlaparoscopic hernia repair without mesh THERAPEUTIC ENDOSCOPIC PROCEDURES ERCP Endoscopic gastrostomy (PEG) + Amoxicillin 1g i.v. stat at (at + Teicoplanin 400mg i.v. stat at Gentamicin and Teicoplanin levels NOT required BREAST SURGERY Breast cancer surgery Breast reshaping procedures Breast surgery with implant (reconstructive or aesthetic) Breast cancer surgery with implant Flucloxacillin 2g i.v. stat at +/- Metronidazole 500mg i.v. stat at (at Flucloxacillin 2g i.v. stat at +/- Metronidazole 500mg i.v. stat at Flucloxacillin 1g i.v. 6hourly +Metronidazole 500mg i.v. 8hourly Until drains are removed Switch to oral antibiotics can be considered at 48 hours Teicoplanin 400mg i.v. stat at +/- Metronidazole 500mg i.v. stat at(at Teicoplanin level NOT required Teicoplanin 400mg i.v. stat at +/- Metronidazole 500mg i.v. stat (at surgeon s Metronidazole 500mg i.v. 8hourly + Teicoplanin 10mg/kg IV (to nearest 100mg: maximum 800mg) for 3 loading doses 12 hours apart then OD Until drains are removed Switch to oral antibiotics should be discussed with Microbiology Teicoplanin levels ARE required * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW (ABW-IBW). 4 of 6

5 VASCULAR SURGERY Lower limb amputation Vascular surgery (abdominal & lower limb) Cardiothoracic Flucloxacillin 1g i.v. stat at + Gentamicin 240mg* i.v. stat at At surgeon s discretion may give up to 2 further doses of Flucloxacillin 500mg i.v. 6hourly + Metronidazole 500mg i.v. 8hourly (No further gentamicin) Teicoplanin 400mg i.v. stat at + + Metronidazole 500mg i.v. at At surgeon s discretion may give up to 2 further doses of Metronidazole 500mg i.v. 8hourly + Teicoplanin 400 mg i.v. one additional dose at 12 hours (No further gentamicin) Cardiac pacemaker insertion Flucloxacillin 1g i.v. stat at Teicoplanin 400mg i.v. stat at Head and neck surgery Head and neck surgery (contaminated & clean contaminated) Complex septorhinoplasty with implant Flucloxacillin 1g i.v. stat at Flucloxacillin 1g iv 6hourly (3 doses) + Metronidazole 500mg i.v. 8hourly (2 doses) Flucloxacillin 1g i.v. stat at Flucloxacillin 1g iv 6hourly (3 doses) + Metronidazole 500mg i.v. 8hourly (2 doses) Flucloxacillin 500 mg p.o. 6hourly for 5 days Head and neck surgery (clean) Clindamycin 900mg i.v. 8hourly (3 doses) Clarithromycin 500 mg i.v. 12hourly (2 doses) + Metronidazole 500mg i.v. 8hourly (3 doses) Clarithromycin 250 mg p.o. 12hourly for 5 days Ear surgery (clean) Ear surgery with Prosthesis Revision surgery Co-Amoxiclav 1.2g i.v. 8hourly (3 doses) Amoxicillin 500 mg p.o. 8hourly for 5 days Nose or sinus surgery Clarithromycin 500 mg i.v. 12hourly (2 doses) + Metronidazole 500mg i.v. 8hourly (3 doses) Clarithromycin 250 mg p.o. 12hourly for 5 days Tonsillectomy Grommet insertion Single dose of topical ofloxacin Single dose of topical ofloxacin * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW (ABW-IBW). 5 of 6

6 References: 1 Scottish Intercollegiate Guidelines Network (SIGN) Antibiotic Prophylaxis in Surgery - Principles, 2008 available online at: 2 National Institute for Health and Clinical excellence (NICE) Surgical Site Infection Prevention and treatment of surgical site infection, October 2008 available on line at: 3 Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonisation and disease following single dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother1991; 35: Health Technology Assessment (HTA) Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials, 1998 available on line at: 5 Zelenitsky S, Ariano R, Godfrey K, et al. Antibiotic Pharmacodynamics in Surgical Prophylaxis: and association between intraoperative antibiotic concentrations and efficacy. Antimicrob Agenst Chemother 2002; 46: Summary of Product Characteristics. Cidomycin adult injectable 80mg/2ml. (accessed 27 January 2009) 7 Wright J, Gray A, Goodey V. Clinical Pharmacy. Pharmaceutical Press Wolf J. S., Bennett C, Dmochowski R, et al. Best practice Policy Statement on Urology Surgery Antimicrobial Prophylaxis. American Urological Association. J. juro 2008; 179: of 6

Recommended Agent First alternative for β-lactam allergy Alternative Agents (in order of preference) document β-lactam allergy for SCIP)

Recommended Agent First alternative for β-lactam allergy Alternative Agents (in order of preference) document β-lactam allergy for SCIP) Surgical Prophylaxis Guideline Updates Wadley Regional Medical Center Surgery and Trauma Committee, July 22, 2014 Pharmacy and Therapeutics Committee, August 2014 Compiled by: Andrea C Jarzyniecki, Pharm

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #21 (NQF 0268): Perioperative Care: Selection of Prophylactic Antibiotic First OR Second Generation Cephalosporin National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL

More information

DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes

DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes NHS ONEL & Barking, Havering & Redbridge University Hospitals Trust Shared Care Guidelines DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED

More information

Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle

Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle Haematology Acute Date Uploaded:

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the

More information

Lovenox weight calculator

Lovenox weight calculator P ford residence southampton, ny Lovenox weight calculator What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings

More information

VIT-0910 STUDY: COUNTRY-SPECIFIC ADDENDUM FOR THE NETHERLANDS

VIT-0910 STUDY: COUNTRY-SPECIFIC ADDENDUM FOR THE NETHERLANDS VIT-0910 STUDY: COUNTRY-SPECIFIC ADDENDUM FOR THE NETHERLANDS Investigational Medicinal Products 1. Paragraph 8.1: The protocol states that all drugs will need to be provided from commercial stock. However,

More information

Enoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections

Enoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections 1. NAME OF THE MEDICINAL PRODUCT Clexane (Lovenox) Syringes Clexane (Lovenox) Forte Syringes 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clexane (Lovenox) Syringes (100mg/ml) 20mg Injection 40mg Injection

More information

Guideline on core SmPC for human fibrinogen products

Guideline on core SmPC for human fibrinogen products 23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation

More information

Presenting SURGICEL Powder

Presenting SURGICEL Powder SURGICEL Powder Presenting SURGICEL Powder Built to stop continuous, broad-surface oozing fast1,2 The next generation of SURGICEL Absorbable Hemostats SURGICEL Powder efficiently and effectively controls

More information

Published 13 June 2011 Page May 2011

Published 13 June 2011 Page May 2011 filgrastim, 30 million units (300 micrograms)/0.5ml, 48 million units (480 micrograms)/0.5ml, solution for injection or infusion in pre-filled syringe (Zarzio ) SMC No. (704/11) Sandoz Ltd 06 May 2011

More information

Verification of Disk Diffusion Tests

Verification of Disk Diffusion Tests Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of

More information

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2 News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes

More information

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. NHS GREATER GLASGOW AND CLYDE BOWEL SCREENING PROGRAMME Clinical Policy Guidelines Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. Date to

More information

Received 26 February 1997/Returned for modification 16 September 1997/Accepted 10 February 1998

Received 26 February 1997/Returned for modification 16 September 1997/Accepted 10 February 1998 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1093 1097 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Comparison of Concentrations of -Ampicillin Administered

More information

BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING

BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING FOR IMMEDIATE RELEASE Media Contact Beth Mueller, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS

More information

Verification of Gradient Diffusion Strips

Verification of Gradient Diffusion Strips Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification

More information

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin Coordinated Primary Options Service DVT Management Plan Management options using Dabigatran or Warfarin Name NHI DOB Ethnicity Gender Address Contact Information Mobile Home Treatment commenced date *CPO

More information

EvaluateMedTech has used a number of sources within the site to develop a 4-level classification tree based on the FDA approvals process.

EvaluateMedTech has used a number of sources within the site to develop a 4-level classification tree based on the FDA approvals process. Classification of Approvals from Devices@FDA FDA Classification EvaluateMedTech has used a number of sources within the Devices@FDA site to develop a 4-level classification tree based on the FDA approvals

More information

Report on New Patented Drugs - Invanz

Report on New Patented Drugs - Invanz Report on New Patented Drugs - Invanz October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB

More information

Autologous transfusion refers to those transfusions in which the blood

Autologous transfusion refers to those transfusions in which the blood The SurgicalTechnologist JUE 2007 254 Intraoperative Autologous Blood Transfusion Margaret Sterling, cst, lpn, ma Autologous transfusion refers to those transfusions in which the blood donor and the transfusion

More information

Minimally Invasive Surgery

Minimally Invasive Surgery Minimally Invasive Surgery 1 RECOOP HST Research Activity Inventory Please complete the template for each selected project your organization would like to share with the partners of the RECOOP HST Consortium

More information

A comparison of CCSD and OPCS Procedure Classifications and an assessment of the mapping challenges.

A comparison of CCSD and OPCS Procedure Classifications and an assessment of the mapping challenges. White Paper Clinical Coding A comparison of CCSD and OPCS Procedure Classifications and an assessment of the mapping challenges. Peter Connor Managing Director Healthcode Ltd Frances Murphy ACC Clinical

More information

ZINACEF GlaxoSmithKline

ZINACEF GlaxoSmithKline ZINACEF GlaxoSmithKline Cefuroxime sodium QUALITATIVE AND QUANTITATIVE COMPOSITION ZINACEF Injection contains 250 mg, 750 mg, 1 g and 1.5 g of cefuroxime (as cefuroxime sodium). ZINACEF MONOVIAL contains

More information

EPIMED: Can DRGs help to improve effectiveness, efficiency and safe use of drugs?

EPIMED: Can DRGs help to improve effectiveness, efficiency and safe use of drugs? EPIMED: Can DRGs help to improve effectiveness, efficiency and safe use of drugs? Innovation and Information Technologies to improve Health Care Management Background High health care costs (growing) Pharmacological

More information

Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis

Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis Journal of Antimicrobial Chemotherapy Advance Access published August 30, 2006 Journal of Antimicrobial Chemotherapy doi:1093/jac/dkl334 Kinetics of galactomannan in surgical patients receiving perioperative

More information

Physician Orders - Adult

Physician Orders - Adult Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy

More information

Board in General Surgery Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons

Board in General Surgery Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons Board General Surgery Royal Australasian College of s, General s Australia & New Zealand Association of General s SUMMARY OF OPERATIVE & NON-OPERATIVE TRAINING EXPERIENCE The required formation must be

More information

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide Journal of Antimicrobial Chemotherapy (2005) 55, Suppl. S2, ii25 ii30 doi:10.1093/jac/dki008 JAC Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

More information

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY

More information

Global Endoscopy Market Report

Global Endoscopy Market Report Global Endoscopy Market Report ----------------------------------------- 2014 View Report Details Executive Summary Endoscopy is a minimally invasive diagnostic medical procedure in which a tube like instrument,

More information

Content on this page requires a newer version of Adobe Flash Player.

Content on this page requires a newer version of Adobe Flash Player. Content on this page requires a newer version of Adobe Flash Player. 13-1-2018 IV vesicants and pain while a vesicant will cause tissue damage if it escapes. Ciprofloxacin is not designated as a vesicant

More information

Revolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics

Revolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics www.polymedix.com Revolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics Ticker: PYMX March 2012 Disclaimer and Safe Harbor Forward-looking statements This presentation contains forward-looking

More information

JAC Surgical prophylaxis in Belgian hospitals: estimate of costs and potential savings

JAC Surgical prophylaxis in Belgian hospitals: estimate of costs and potential savings Journal of Antimicrobial Chemotherapy (1998) 41, 267 272 JAC Surgical prophylaxis in Belgian hospitals: estimate of costs and potential savings A. Sasse a, R. Mertens a *, J. P. Sion b, O. Ronveaux a,

More information

ASERNIP-S. Australian Safety & Efficacy Register of New Interventional Procedures - Surgical. Royal Australasian College of Surgeons

ASERNIP-S. Australian Safety & Efficacy Register of New Interventional Procedures - Surgical. Royal Australasian College of Surgeons ASERNIP-S Australian Safety & Efficacy Register of New Interventional Procedures - Surgical Member of International Network of Agencies for Health Technology Assessment Australia Population 23 million

More information

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005 ANTICOAGULANT THERAPY REVISITED 2005 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most

More information

PLTW Biomedical Science Medical Interventions Course Outline

PLTW Biomedical Science Medical Interventions Course Outline Follow the fictitious Smith family as you learn about the prevention, diagnosis, and treatment of disease. Play the role of biomedical professionals to analyze case information and diagnose and treat your

More information

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network, Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients

More information

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) 23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular

More information

Technique of enteral nutrition

Technique of enteral nutrition Life Long Learning Module 8.3 Technique of enteral nutrition Johann Ockenga, MD Dep.. of Gastroenterology, Hepatology & Endocrinology Universitätsmedizin tsmedizin Berlin Germany Copyright 2006 by ESPEN

More information

Press Release

Press Release Press Release www.shire.com This press release is intended for a global audience. Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric

More information

10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics

10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical

More information

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) 1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous

More information

Anti- THrombosis with Enoxaparin in intubated Adolescents

Anti- THrombosis with Enoxaparin in intubated Adolescents Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question

More information

TAYSIDE GUIDE TO MASSIVE TRANSFUSION/BLOOD LOSS

TAYSIDE GUIDE TO MASSIVE TRANSFUSION/BLOOD LOSS HTC 11/02 TAYSIDE GUIDE TO MASSIVE TRANSFUSION/BLOOD LOSS This local guide should be used in conjunction with the guidelines published by the British Committee for Standards in Haematology. Definition:

More information

Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection

Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical

More information

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary

More information

Regulatory hurdles and opportunities

Regulatory hurdles and opportunities Regulatory hurdles and opportunities Professor Roger Finch Nottingham University Hospitals & University of Nottingham, UK Drug licensing and regulation Mandatory for market authorisation Supports the public

More information

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Jack L. Cronenwett, MD Medical Director, Society for Vascular

More information

Guidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients

Guidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients Guidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients The recombinant human granulocyte-colony stimulating factor (GCSF) of choice is Biosimilar filgrastim

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Forte Syringes 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pre-filled syringes: 120 mg Injection Enoxaparin sodium 120 mg (equivalent

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS

MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS HLC170B January 2017 Vijay Laxmi Project Analyst ISBN: 1-62296-410-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

MDR ID: Definition: Applicable:

MDR ID: Definition: Applicable: MDR Classification: (Reference Medical Device Regulation EU 2017/745, Annex VIII) Product: Product Name 1. DURATION OF USE MDR ID: Definition: Applicable: - Invasive Device: Continue Go to 2. Invasive

More information

Off Label or On Target? The Ethics of Investigational and Compassionate Uses

Off Label or On Target? The Ethics of Investigational and Compassionate Uses Off Label or On Target? The Ethics of Investigational and Compassionate Uses G. Kevin Donovan, MD, MA Director, Pellegrino Center for Clinical Bioethics Professor of Pediatrics Georgetown University School

More information

Soft Tissue Retaining Set

Soft Tissue Retaining Set U.S. Toll Free 866-GOLIMBS Laparoscopic Surgery Soft Tissue Retaining Set Part No: 50151 For securing synthetic soft tissue components used in intermediate surgical training and laparoscopic trainers.

More information

Bringing True Novelty to the Anti-Infective Space

Bringing True Novelty to the Anti-Infective Space Bringing True Novelty to the Anti-Infective Space New Class of Antibacterials Based on a Unique Mechanism of Action Dr Dawn Firmin SMi s 17 th Annual Conference on Superbugs & Superdrugs March 2015 1 Contents

More information

Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi

Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi Need for public-private collaboration Challenges of AB

More information

6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics

6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Clexane Syringes 100mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 20mg Injection 40mg Injection 60mg Injection

More information

DATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

DATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION DATA SHEET 1 CLEXANE AND CLEXANE FORTE * 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CLEXANE Pre-filled syringes, ready-to-use: 20 mg injection enoxaparin sodium 20mg (equivalent to 2,000 IU anti-xa activity)

More information

The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital*

The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital* CHEST The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital* Maureen A. Smythe, PharmD, FCCP; John M. Koerber, PharmD; and Joan C. Mattson, MD Original

More information

Laminar flow in orthopaedic operations - Essential if you can afford it. Peter Hoffman Consultant Clinical Scientist Public Health England

Laminar flow in orthopaedic operations - Essential if you can afford it. Peter Hoffman Consultant Clinical Scientist Public Health England Laminar flow in orthopaedic operations - Essential if you can afford it Peter Hoffman Consultant Clinical Scientist Public Health England Up until the 1950s in the UK (and elsewhere) Surgical instruments

More information

INTRODUCTION TO CLINICAL PHARMACY

INTRODUCTION TO CLINICAL PHARMACY CHAPTER 1 INTRODUCTION TO CLINICAL PHARMACY Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness, and disease

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 19 March 2009 EMEA/CHMP/BMWP/118264/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR BIOLOGICAL

More information

What is an Investigational Drug? 21CFR312.3(b)

What is an Investigational Drug? 21CFR312.3(b) Review of the Investigational Drug and Device Regulations Changes to the RSRB Online Submission System (ROSS) Application for Drugs and Devices Kelley O'Donoghue Donoghue, Director OHSP, MPH, CIP and Tiffany

More information

High Cost Drugs Clinical Coding Standards and Guidance OPCS-4

High Cost Drugs Clinical Coding Standards and Guidance OPCS-4 High Cost Drugs Clinical Coding Standards and Guidance OPCS-4 Clinical Classifications Service Date 6 th March 2014 1 Copyright 2014, Health and Social Care Information Centre. Contents Introduction...

More information

DME REGIONAL Carrier. DME REGIONAL Carrier. service (not separately payable). If other. DME REGIONAL Carrier. DME REGIONAL Carrier

DME REGIONAL Carrier. DME REGIONAL Carrier. service (not separately payable). If other. DME REGIONAL Carrier. DME REGIONAL Carrier A0021 - A0999 Ambulance Services Local Carrier A4206 - A4209 Medical, Surgical, and Self- Local Carrier if incident to a physician s Administered Injection Supplies A4210 Needle Free Injection Device A4211

More information

Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request

Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Multidose Vial 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Vials containing 300 mg enoxaparin (equivalent to 30,000 IU anti-xa

More information

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this

More information

Type: Embedded within the selected substance, indicated when creating the substance.

Type: Embedded within the selected substance, indicated when creating the substance. Overview: Substance Table: Each procedure will include a substance table, either on the main page of the procedure (immediately after selecting the procedure type), embedded elsewhere within a procedure,

More information

SCOPEBOX All-in-One Laparoscopy Unit

SCOPEBOX All-in-One Laparoscopy Unit LAP 70 1.2 11/2017-E SCOPEBOX All-in-One Laparoscopy Unit The solution for extra-hospital laparoscopic surgery Introduction Laparoscopic surgery has become increasingly popular worldwide over the last

More information

NUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014

NUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014 NUH PHARMACY CLINICAL TRIALS Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014 Dedicated pharmacy trials staff Lead Pharmacist, Service Co-ordinator Pharmacists: Band 7 and 8a Technicians:

More information

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug? Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental

More information

Tranexamic Acid in Joint Replacement Surgery. Donna Berta Blood Conservation Program Coordinator

Tranexamic Acid in Joint Replacement Surgery. Donna Berta Blood Conservation Program Coordinator Tranexamic Acid in Joint Replacement Surgery Donna Berta Blood Conservation Program Coordinator Today s Objectives After this presentation participants will be able to: to describe the basic physiology

More information

Investor Presenta,on. Dawson Reimer President & COO. Albert D. Friesen, PhD. Chair & CEO

Investor Presenta,on. Dawson Reimer President & COO. Albert D. Friesen, PhD. Chair & CEO Investor Presenta,on Albert D. Friesen, PhD Chair & CEO Dawson Reimer President & COO March 31, 2015 Disclaimer This presentation is for informational purposes only and should not be considered as an offer

More information

Mithra manages today multiple synergistic innovation streams for R&D, manufacturing or commercial partnering

Mithra manages today multiple synergistic innovation streams for R&D, manufacturing or commercial partnering Mithra manages today multiple synergistic innovation streams for R&D, manufacturing or commercial partnering Our mission is to improve every stage of women s life with innovative and accessible pharmaceutical

More information

Design and Dosage Form. Dr. Deny Susanti

Design and Dosage Form. Dr. Deny Susanti Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:

More information

Histoacryl A revolution in mesh fixation

Histoacryl A revolution in mesh fixation Histoacryl A revolution in mesh fixation Closure Technologies Histoacryl A revolution in mesh fixation A new indication for a classic product Histoacryl has been used for more than 40 years in operating

More information

Demand Management Plan for Immunoglobulin Use

Demand Management Plan for Immunoglobulin Use Demand Management Plan for Immunoglobulin Use BACKGROUND Availability of immunoglobulin to the NHS Therapeutic immunoglobulin, a blood product, is used effectively in the treatment of a wide range of diseases.

More information

Holmium laser prostatectomy

Holmium laser prostatectomy NHS National Institute for Clinical Excellence Holmium laser prostatectomy Understanding NICE guidance information for men considering the procedure, and for the public November 2003 Holmium laser prostatectomy

More information

Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852

Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 May 24, 2012 Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Re: Comments on Docket #FDA- 2012 D 0148; Draft Guidance for Industry

More information

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season BIOPHARMACEUTICS AND PHARMACOKINETICS Degree in PHARMACY University of Alcalá Academic year 2016/17 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code: 570014 Degree:

More information

FOCUS ON MRSA/SA SSTI ASSAY FAILURE IN PROSTHETIC JOINT. Institute of Microbiology, Lille University Hospital, F Lille, France

FOCUS ON MRSA/SA SSTI ASSAY FAILURE IN PROSTHETIC JOINT. Institute of Microbiology, Lille University Hospital, F Lille, France JCM Accepted Manuscript Posted Online 16 November 2016 J. Clin. Microbiol. doi:10.1128/jcm.01658-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. FOCUS ON MRSA/SA SSTI ASSAY FAILURE

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 29 June 2000 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED

More information

MIIG INJECTABLE Graft The following languages are included in this packet:

MIIG INJECTABLE Graft The following languages are included in this packet: MIIG INJECTABLE Graft 128801-10 The following languages are included in this packet: English (en) Deutsch (de) Nederlands (nl) Français (fr) Español (es) Italiano (it) Português (pt) 中文 - Chinese (sch)

More information

Bacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections

Bacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections Bacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections November 7, 2017 NYSE MKT: APHB Safe Harbor Statement This presentation contains forward-looking statements that involve risks,

More information